Gastroenterology

A proportion of patients reported triggering or worsening symptoms after a meal, with the largest proportion experiencing bloating or distention, followed by abdominal pain or discomfort, and epigastric pain.

No statistically significant differences in infusion reaction, serious reaction, or immunogenicity rates were identified between patients switching to an infliximab biosimilar and those who continued treatment on the originator.

The risk of developing high grade dysplasia or esophageal adenocarcinoma was higher in patients with Barrett’s esophagus with immunosuppressant medication use.

No statically significant differences in ESR, CRP, TNF levels, and albumin were observed pre- and post-switch from the infliximab originator to the biosimilar.

At the 12-month mark, 52% of patients in the axSpA cohort and 76% of those in the IBD cohort achieved clinical remission.

Small molecule therapies offer patients with mild or moderate inflammatory bowel disease a much cheaper alternative to biologics.

Artificial intelligence is being used to help detect polyps for patients undergoing a colonoscopy.

A diet that is high in sugar, fried foods, and lacks vegetables increases the risk of pediatric inflammatory bowel disease.

Patients with moderate to severe PCM to go along with the AAH were significantly more likely have a number of vitamin deficiencies, including in vitamin D, vitamin B12, and folate.

Dupilumab became the first approved treatment for eosinophilic esophagitis in 2022.

New research from a first-in-human study of a novel procedure involving electroporation of the superficial layer of the mucosa in the small intestine could help eliminate need for insulin in some people with type 2 diabetes.

Experts in hepatology comment on effectiveness of diagnostic testing hepatic encephalopathy.

Expert hepatologists discuss how to identify patients with hepatic encephalopathy who require hospitalization vs outpatient care.

All countries in Africa now provide a three-dose infant hepatitis B vaccination beginning at age 6-8 weeks.

James Williams, MS, DO, FACEP, comments on current treatment options and treatment selection for hepatic encephalopathy.

Arun Jesudian, MD, and James Williams, MS, DO, FACEP, review the AASLD and EASL guideline approaches to the management of overt hepatic encephalopathy (HE) and comment on the grading of HE based on presentation.

There were also 9 RT176 strains that carried the cfr(E)gene and one RT001 strain carried the cfr(C) gene. However, they were without a linezolid resistance.

Expert gastroenterologists delve into the long-term management of Crohn’s disease and ulcerative colitis and examine the latest treatment options and strategies to enhance patient outcomes.

The geometric mean duration of single-occupancy room isolation was 1.8 days in the mPOCT group, compared to 2.6 days in the control group.

There remains a need for more biosimilars in gastroenterology.

RBX2660 and Vowst are now both approved for the prevention of recurrent C. difficile infections.

Kimberly A. Brown, MD, comments on the life-threatening nature of recurrent HE and how to navigate patient conversations.

Experts in hepatology discuss the pathophysiology of HE and how certain factors influence the brain in HE.

The treatment is the second live microbiota therapeutic approved by the FDA, coming just a few months after the agency approved RBX2660 for recurrent C. difficile infections.

Dr James Williams shares insight on factors leading to delays in hepatic encephalopathy (HE) diagnosis, the importance of early detection, and strategies to improve diagnosis in the in-patient setting.

An expert in emergency medicine outlines his approach to the clinical evaluation of hepatic encephalopathy.

The results also show 10.3% of the patients with celiac disease that was histopathological confirmed were seronegative to Anti-TtG-IgA, but seropositive to anti-DGP-IgA and/or Anti-DGP-IgG.

Dr Paul Feuerstadt joins Dr David Hudesmand and Dr Jordan Axelrad in a discussion about treatment approaches for C difficile infections, and the latest advances in treating recurrent infections with fecal microbiota transplantation.

In addition, 17 female patients who completed PENFS showed improvements in various symptoms, such as pain, disability, and catastrophizing, while carbohydrate degradation and LCFA synthesis pathways decreased in the post-treatment and follow-up analysis.

There were significant positive associations found of overweight, obesity, and a 5-unit increase in BMI with colorectal cancer risk when using BMI measured 8-10 years prior to diagnosis.